Acumen Pharmaceuticals Sets June 4th Annual Meeting
Ticker: ABOS · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1576885
| Field | Detail |
|---|---|
| Company | Acumen Pharmaceuticals, INC. (ABOS) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Acumen Pharma's proxy statement is out for the June 4th shareholder meeting. Vote wisely.
AI Summary
Acumen Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for its annual meeting of stockholders scheduled for June 4, 2025. The filing details the company's governance and matters to be voted on by shareholders. Acumen Pharmaceuticals is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals or director elections, allowing them to make informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating immediate financial distress or significant new risks.
Key Numbers
- 0001576885-25-000057 — Accession Number (Unique identifier for this SEC filing)
- 20250423 — Filing Date (Date the proxy statement was filed with the SEC)
Key Players & Entities
- Acumen Pharmaceuticals, Inc. (company) — Registrant
- April 23, 2025 (date) — Filing Date
- June 4, 2025 (date) — Annual Meeting Date
- 427 Park St. (address) — Company Business Address
- Charlottesville, VA (location) — Company Location
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit votes from shareholders for their annual or special meetings.
When is Acumen Pharmaceuticals' Annual Meeting of Stockholders scheduled?
The Annual Meeting of Stockholders for Acumen Pharmaceuticals is scheduled to be held on June 4, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 23, 2025.
What is the primary business of Acumen Pharmaceuticals, Inc.?
Acumen Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
Where is Acumen Pharmaceuticals, Inc. located?
Acumen Pharmaceuticals, Inc. is located at 427 Park St., Charlottesville, VA 22902.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding Acumen Pharmaceuticals, Inc. (ABOS).